Furthermore, our observations indicated that tumor volumes in patients with high TSP50/p-AKT/ALDH1 expression were 2-times larger than those in patients with low TSP50/p-AKT/ALDH1 expression, which was consistent with the comparable changes in Ki67 levels (Grade III, 40% (10/25) vs. 30% (7/23)) (Fig. 12E-G). The gene discussed is PRSS50; the disease is neoplasm.